How has been the historical performance of ERIS Lifescience?

Answer:The historical performance of ERIS Lifescience shows significant growth in net sales and operating profit over the years, with net sales reaching 2,893.64 Cr in March 2025, up from 1,074.06 Cr in March 2020. The operating profit (PBDIT) also increased to 1,035.56 Cr in March 2025 from 383.78 Cr in March 2020. However, the profit after tax (PAT) saw fluctuations, peaking at 406.11 Cr in March 2022 before declining to 351.84 Cr in March 2025. The company's total assets grew to 6,744.13 Cr in March 2025, compared to 1,381.39 Cr in March 2020, while total liabilities increased to 6,744.13 Cr from 1,381.39 Cr in the same period. The cash flow from operating activities improved significantly, reaching 1,065.00 Cr in March 2025, compared to 271.00 Cr in March 2020.

Breakdown:
ERIS Lifescience has demonstrated a robust growth trajectory in its financial performance over the years. From March 2020 to March 2025, net sales surged from 1,074.06 Cr to 2,893.64 Cr, reflecting a strong demand for its products. Operating profit (PBDIT) also showed a positive trend, increasing from 383.78 Cr to 1,035.56 Cr, indicating improved operational efficiency. Despite this growth, profit after tax (PAT) fluctuated, with a peak of 406.11 Cr in March 2022, followed by a decrease to 351.84 Cr in March 2025. The company's total assets expanded significantly, reaching 6,744.13 Cr, while total liabilities mirrored this growth, also standing at 6,744.13 Cr. Cash flow from operating activities saw a notable increase, rising from 271.00 Cr in March 2020 to 1,065.00 Cr in March 2025, showcasing enhanced cash generation capabilities.